ArticleJournal of translational medicine2026
C3
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMetastatic cervical cancer remains a leading cause of cancer-related death in women, although several mouse models of metastatic cervical cancer exist, many fail to preserve an immunocompetent primary tumor microenvironment, limiting their ability to adequately model metastatic progression. This study aimed to establish a syngeneic orthotopic cervical cancer model that faithfully reproduces the metastatic cascade and defines cellular interactions associated with metastasis in tumor microenvironment.
methodsU14 cells derived from mouse cervical cancer were engineered to stably express luciferase (U14-Luc) for the detection of micrometastases via bioluminescence imaging. The syngeneic orthotopic mouse model was established by intra-cervically injecting U14-Luc into immunocompetent C57BL/6 mice under direct visualization. Primary and metastatic tumor burden were detected by in vivo or ex vivo organ bioluminescence imaging. Histological analysis of tumor tissues was performed using Hematoxylin-Eosin staining. Single-cell RNA sequencing was used to identify cellular interactions and molecular pathways in primary tumors (PTs) and paired lymph node metastasis tumors (LNMTs).
resultsIn this mouse model, primary tumors consistently developed near the external cervical os and vaginal fornix. By day 14 post-injection, cancer cells had invaded into the pelvic viscera, particularly the rectum, and disseminated to regional lymph nodes. By day 28, distant metastases, predominantly in the lungs, were observed. Single-cell analysis revealed that crosstalk between cancer cells and T cells in LNMT promoted immune escape via the SPP1 pathway. Additionally, a C3
conclusionsThis syngeneic orthotopic mouse model effectively replicates the metastatic cascade of cervical cancer. Its ability to closely mimic the tumor microenvironment makes this model a valuable immunocompetent orthotopic platform for investigating the metastatic mechanism and evaluating novel therapeutic strategies for cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.